MedTrace Logo

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

NCT06979076 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-29

No results posted yet for this study

Summary

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions

  • CLL (Chronic Lymphocytic Leukemia)
  • SLL (Small Lymphocytic Lymphoma)

Interventions

DRUG

MS-553, DS1

Oral, Dose Schedule 1

DRUG

MS-553, DS2

Oral, Dose Schedule 2

Sponsors & Collaborators

  • MingSight Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-09-30
Completion
2028-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06979076 on ClinicalTrials.gov